Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events
Read More »Sitagliptin May Cut Mortality in T2DM Patients With COVID-19
Sitagliptin at time of hospitalization linked to reduced mortality, improved clinical outcomes
Read More »FDA Warns Companies About Illegal Sales of Dietary Supplements
The supplements contain cesium chloride, but no cesium chloride-containing products are FDA-approved
Read More »DKA Episode May Harm Cognitive Function in Children With T1D
Lower IQ and worse memory seen in children with newly diagnosed type 1 diabetes and single event
Read More »Disparities in Insulin Pump Use Persist, 2005 to 2019
Use higher among White children with type 1 diabetes versus Black and Hispanic children
Read More »T2DM Links to Risk for Dementia Differ by Type, Glycemic Control
Dose-response association shows higher risk for dementia with HbA1c >87 versus <52 mmol/mol
Read More »Manufacturer Prices for Insulin Substantially Higher in the U.S.
Manufacturer prices more than eight times higher in the U.S. than in other high-income countries
Read More »28 Percent With T1DM Received Remote Care in Pandemic
Most patients found remote appointments useful and planned to have remote appointments in the future
Read More »Unemployment Linked to Increases in Pediatric Hospitalizations
Hospitalizations increased for four economy-sensitive conditions, including substance abuse, diabetes
Read More »Time-Restricted Eating May Not Aid Weight Loss
Findings also did not show benefit for cardiometabolic markers
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.